This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND, Jan. 27, 2025 /PRNewswire/ -- Quest...
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J., Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30,...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...
New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ --...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January...
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month...
Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from...
The Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) applauds the National Comprehensive Cancer Network (NCCN) for recent updates to its Genetic/Familial High-Risk...
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and...
Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J., Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the...
Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va., Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE:...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS. The transaction, valued at...
Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and CLEVELAND, Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics...
Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount...
Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October...
One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns SECAUCUS, N.J., Aug....
Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J., Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a...
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a...
Second quarter revenues of $2.40 billion, up 2.5% from 2023 Second quarter reported diluted earnings per share ("EPS") of $2.03, down 1.0% from 2023; and adjusted diluted EPS of $2.35, up 2.2%...